Next Article in Journal
Low CD25 in ALK+ Anaplastic Large Cell Lymphoma Is Associated with Older Age, Thrombocytopenia, and Increased Expression of Surface CD3 and CD8
Previous Article in Journal
Fatty Pancreas: Its Potential as a Risk Factor for Pancreatic Cancer and Clinical Implications
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Electrochemotherapy in the Management of Keratinocyte Carcinomas: A Systematic Review

by
Yue Ting Nichole Tan
1 and
Choon Chiat Oh
2,*
1
Duke-NUS Medical School, Singapore 169857, Singapore
2
Department of Dermatology, Singapore General Hospital, Singapore 169608, Singapore
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(11), 1766; https://doi.org/10.3390/cancers17111766
Submission received: 3 May 2025 / Revised: 21 May 2025 / Accepted: 22 May 2025 / Published: 24 May 2025
(This article belongs to the Topic Recent Advances in Anticancer Strategies, 2nd Edition)

Simple Summary

Electrochemotherapy (ECT) is an emerging treatment modality for skin cancer, yet robust evidence on its role in keratinocyte carcinomas remains limited. Through studies encompassing diverse patient demographics and tumor characteristics, this review demonstrates that ECT is effective and tolerable in the treatment and palliation of keratinocyte carcinomas. This review also provides guidance for future research, emphasizing the need to enhance reporting quality, optimize treatment protocols, and investigate long-term outcomes.

Abstract

Background: Keratinocyte carcinomas, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), presents a growing concern. Electrochemotherapy (ECT), an emerging treatment modality, combines chemotherapy and electroporation to enhance drug delivery into cells. However, reviews evaluating ECT in keratinocyte carcinomas are lacking. Objectives: This study reviews the efficacy and toxicity of ECT in the treatment and palliation of keratinocyte carcinomas. Methods: A systematic search was conducted across PubMed, Cochrane, Embase, and Scopus databases. Patient, tumor, and treatment characteristics, tumor response, long-term disease outcomes, and toxicity data were extracted. Quality of studies was assessed using validated tools. Primary endpoints included tumor response; secondary endpoints included long-term disease outcomes and toxicity. Results: Twenty-one studies were included. Complete response (CR) rates ranged from 50 to 100% and from 10 to 100% for BCC and SCC, respectively. OS rates ranged from 95 (14 months) to 100 (1 year) % and from 64 (1 year) to 85.1 (8.6 months) % for BCC and SCC, respectively. One-year local disease-free survival (LDFS) rates were 89% and 87% for BCC and SCC, respectively. For BCC, local progression-free survival (LPFS) rates were 96% (1 year), 90% (2 year), and 70% (5 year). For SCC, 1-year LPFS rates were 80% on a per-patient basis and 49% on a per-lesion basis. Conclusions: ECT is effective and tolerable in the treatment and palliation of keratinocyte carcinomas. Future studies should focus on improving reporting quality, optimizing treatment protocols, and investigating long-term outcomes.

1. Introduction

Keratinocyte carcinomas, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are among the most common malignancies in White populations [1]. Their incidence is on the rise, driven by prolonged ultraviolet (UV) exposure, global warming, and an aging population [2].
Surgical resection remains the standard treatment for primary skin malignancies [3], but its feasibility is dependent on tumor characteristics and patient co-morbidities. Additionally, resistance to standard treatments is growing, with locally advanced and metastatic BCC and SCC showing increasing resistance to traditional therapies [4,5,6,7]. BCC has also developed resistance to newer therapies such as hedgehog inhibitors [8]. Moreover, toxicities associated with systemic chemotherapy and immunotherapy can negatively impact patients’ quality of life (QoL) [9].
Given these challenges, there is an increasing need for alternative treatment modalities that can provide effective tumor control while minimizing systemic side effects. Electrochemotherapy (ECT) combines chemotherapy and electroporation, utilizing electric pulses to increase the permeability of cancer cell membranes to chemotherapeutic agents such as bleomycin and cisplatin [10,11,12,13]. First conceptualized in the 1980s, ECT is a relatively new cancer treatment modality [14]. Originally indicated for inoperable skin cancer, it is now also used in the treatment and palliation of skin metastases [12,15]. ECT also confers local cancer control with minimal damage to surrounding tissues [16,17]. However, treatment protocols have varied across studies, particularly in terms of the chemotherapeutic agent used, electrode type, and electric pulse parameters. These variations may influence treatment efficacy, contributing to differences in clinical outcomes reported across studies. To standardize clinical practice, the European Standard Operating Procedures in Electrochemotherapy (ESOPE) guidelines were developed to ensure that the use of ECT in the management of skin cancer is consistent and optimized [18].
Recent reviews and meta-analyses on ECT in metastatic melanoma have reported overall response (OR) rates of 77.6–80.6% and 1-year overall survival (OS) rates of 67–89% [19,20]. However, reviews focusing specifically on the effects of ECT in keratinocyte carcinomas are sparse. A previous review on ECT in BCC found outcomes comparable to those achieved with conventional surgery, but studies included were few and with heterogenous methods of data reporting [21]. No reviews have also examined the role of ECT in SCC.
Therefore, this study aims to systematically review the current literature on the efficacy and toxicity of ECT in the treatment and palliation of keratinocyte carcinomas. Variables including patient and tumor characteristics, treatment parameters, tumor response, long-term disease outcomes, and treatment-related toxicities will be assessed to identify patterns influencing treatment outcomes and to highlight areas of variability across studies in order to inform future research and optimization of ECT protocols in the management of BCC and SCC.

2. Materials and Methods

2.1. Search Strategy and Study Selection

A systematic search of the PubMed, Cochrane, Embase, and Scopus databases from the earliest date to 24 March 2024 was performed using search terms (‘electrochemotherapy’ AND (‘skin’ AND ‘cancer’)). Retrospective and prospective studies and clinical trials published with full text in English between 1 January 2014 to 31 December 2023 on ECT in the management of primary and metastatic BCC and SCC were included. Systematic or narrative reviews, meta-analyses, case reports, letter-commentaries-editorials, meeting abstracts, and guidelines-recommendations were excluded. Studies with a sample size of <10, in vitro and veterinary studies, as well as studies which lacked reporting on tumor response or long-term disease outcomes were also excluded. Two reviewers (NT, CC) independently reviewed records, removed duplicates, and selected articles at the title/abstract level. Discrepancies were resolved by discussion. Protocol for this review was registered with PROSPERO (registration number CRD42024567182).

2.2. Data Extraction

The data were extracted from studies on the use of ECT among patients with BCC and SCC. In studies that included patients with other non-keratinocyte skin cancers, data specific to BCC and SCC were extracted, wherever possible. The data included patient and tumor characteristics (age, site, size, and number of tumors, type and stage of cancer), ECT characteristics (drug, dose, and route of administration, electroporator, electrode, number of cycles, type of anesthesia), and the presence of previous or concurrent therapies. The data on tumor response after the first ECT cycle in terms of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) rates, according to the Response Evaluation Criteria in Solid Tumors (RECIST), were extracted. Duration of follow-up and long-term disease outcomes, including OS, local progression-free survival (LPFS) and local disease-free survival (LDFS) rates, and treatment toxicity were extracted.

2.3. Quality Assessment

Quality of studies was assessed using the Version 1 of the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) assessment tool [22] for observational studies, and the Version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2) assessment tool for randomized controlled trials (RCTs) [23], as recommended by the Cochrane Handbook [24]. The ROBINS-I tool evaluates bias across seven domains, including the risk of bias due to confounding, deviations from intended interventions, missing data, and the risk of bias in the selection of participants, classification of interventions, measurement of outcomes, and selection of the reported result. Studies were then categorized as having low, moderate, serious, or critical risk of bias. The RoB 2 tool evaluates bias across five domains, including the risk of bias due to deviations from the intended intervention and due to missing outcome data, the risk of bias in the measurement of the outcome and the selection of reported results, and the risk of bias arising from the randomization process. Studies were then categorized as having a low risk of bias, some concerns, or a high risk of bias.

2.4. Statistical Analysis

The primary endpoints were tumor response to ECT in terms of CR, PR, SD, and PD rates. The secondary endpoints were long-term disease outcomes in terms of OS, LPFS, and LDFS rates, and treatment toxicity.

3. Results

3.1. Included Studies

The search results are shown in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow-chart (Figure 1). From an initial search of 1003 records and after removing duplicates, 651 were screened at the title/abstract level. In total, 624 were excluded for not meeting the inclusion criteria; two lacked full text; 3 were meeting abstracts; and 1 lacked data on tumor response to ECT and long-term disease outcomes. A total of 21 studies were included: 1 RCT [25], 3 single-arm trials [26,27,28] and 10 prospective [16,29,30,31,32,33,34,35,36,37] and 7 retrospective [38,39,40,41,42,43,44] cohort studies.

3.2. Risk of Bias of Included Studies

Three observational studies had a serious risk of bias: two from confounding [34,44] and one from missing data [27]. Apart from one study, which had low risk [32], the rest of the observational studies had a moderate risk of bias. The RCT had some risk of bias arising from deviations from the intended deviation, missing outcomes, and from outcome measurement [25].

3.3. Patient and Tumor Characteristics

Patient and tumor characteristics for BCC and SCC are presented in Table 1 and Table 2, respectively.
A total of 1890 patients, aged 11–104, were included. Four studies included only patients with BCC [25,29,31,41], two included only SCC [37,44], and two included only BCC and SCC [32,33]. The remaining included other skin cancers. Four treated patients with palliative intent [26,28,38,41]; the rest with curative intent.
Apart from five studies which did not report on the number of treated tumors [35,38,39,40,43], 5629 tumors in the head-and-neck region, trunk, and extremities, were treated and ranged from 1 to 60 per patient. Tumor diameters ranged from 2 to 500 mm.

3.4. Treatment Characteristics

Treatment characteristics for BCC and SCC are presented in Table 3 and Table 4, respectively. While most patients included in the studies had previously undergone treatments such as surgery, chemotherapy, radiotherapy, and immunotherapy, ECT was used as the primary treatment modality during the study period in most patients where it was administered as monotherapy, except for in two studies where it was combined with other therapies such as surgery [30], immunotherapy, chemotherapy, and photodynamic therapy [26]. One study used the ePORE electroporator (Mirai Medical, Galway) [27] and another used the Sennex electroporator (BIONMED Technologies GmbH, Saarbrücken, Germany) [43], while the rest used the Cliniporator (IGEA GmbH, Frankfurt am Main, Germany). All studies delivered ECT in accordance with the ESOPE guidelines [18], except for one, which used high-frequency electroporation instead of the traditional low-frequency electroporation [27].
Except one study which also used cisplatin [30], all exclusively used bleomycin. Bleomycin was typically administered intravenously at 15,000 IU/m2 (range: 7500–30,000 IU/m2). Two compared reduced- and standard-dose bleomycin (10,000 vs. 15,000 IU/m2) [32,33]. When administered intratumorally, the typical dose was 1000 IU (range: 250–5000 IU). Electrodes were mainly arranged in hexagonal and linear arrays. Most patients received one ECT cycle (range: 1–6).

3.5. Outcomes

3.5.1. Tumor Response

Tumor response, long-term disease outcomes, and toxicity data for BCC and SCC are presented in Table 5 and Table 6, respectively. All studies used the RECIST scale to evaluate tumor response. Response was typically evaluated at 30–90 days post-ECT. CR rates ranged from 50 to 100% in BCC and 10–100% in SCC. Most reported a PD rate of 0%, with the highest rate at 9.5% in a study involving SCC patients with tumors greater than 3 cm in diameter [16].
Follow-up duration ranged from 165 days to up to 5 years. OS rates ranged from 95% (14 months) to 100% (1 year) among BCC patients [16,37], and from 64% (1 year) to 85.1% (8.6 months) among SCC patients [16,37]. One-year LDFS rates were reported at 89% for BCC, and 87% for SCC [16]. For BCC, LPFS rates ranged from 96% (1 year) to 90% (2 year) and to 70% (5 year) [31,41]. For SCC, 1-year LPFS rates were reported at 80% on a per-patient basis and 49% on a per-lesion basis [37].

3.5.2. Internal Comparisons

An RCT compared ECT to surgical excision and found similar CR rates in patients with primary BCC [25]. Another study also compared reduced- and standard-dose bleomycin in BCC and SCC patients and found similar CR rates [33]. Another compared outcomes between patients aged <90 years and ≥90 years but did not report outcomes specifically pertaining to BCC and SCC [39].

3.5.3. Toxicity

Eleven studies evaluated adverse events with the Common Terminology Criteria for Adverse Events (CTCAE) [16,25,30,31,33,35,37,39,40,41,44] and five studies reported on the most frequent adverse events [26,29,38,42,43], with pain hyperpigmentation, and erythema being the most common toxicities.

4. Discussion

These studies highlight the broad applicability of ECT in treating keratinocyte carcinomas, featuring diverse patient and tumor characteristics. Although the recent registry-based studies in this review demonstrate its real-world efficacy and tolerability [31,35,37], there remains a paucity of RCTs comparing ECT to other established treatments.
Currently, ECT is recognized for treating various tumor histotypes and palliating skin metastases. However, only a minority of patients in the studies reviewed were treated with palliative intent, limiting definitive conclusions on its palliative role.
All studies reviewed treated head-and-neck tumors, which presents unique challenges due to the anatomical complexity of the region and the risk of cutaneous ECT-related side effects. Since BCC and SCC are commonly located in the head-and-neck region [45], these studies improve our understanding of using ECT to treat these tumors.
Studies varied in drug and electrode usage, anesthesia, number of ECT cycles, and the presence of prior and concurrent treatments. Most used intratumoral or intravenous bleomycin, with one using intratumoral cisplatin. According to the ESOPE guidelines, intravenous injection is only recommended for bleomycin, possibly explaining its more widespread use [18]. However, cisplatin remains an alternative for patients where the use of systemic bleomycin may be unfavorable, such as those with pulmonary or renal disease due to its toxicities [46].
Two studies investigated reduced bleomycin doses [32,33] and one found no significant difference in tumor control among elderly BCC and SCC patients [33]. These findings are supported by a prior bleomycin pharmacokinetics-based study which found equivalence between standard and reduced doses in elderly patients due to reduced renal clearance with age [47].
Studies mostly used needle electrodes of varying arrays, primarily in linear and hexagonal configurations. According to the updated ESOPE guidelines, linear array electrodes are recommend for smaller tumors, particularly in the head-and-neck region, as their relatively lower applied voltage results in minimal or no hyperpigmentation [48]. In contrast, hexagonal array electrodes are preferred for larger tumors, given their ability to cover a wider treatment area [48].
Outcomes varied based on tumor size. One study reported an OR rate of 66.7% among BCC patients with larger tumors (>3 cm) compared to 93.5% among those with smaller tumors (≤3 cm) [16]. A similar trend was observed in SCC patients (28.6% vs. 76.9%) [16]. On the other hand, studies treating smaller tumors with median diameters of 1–2.5 cm reported OR rates of 100% among SCC patients [33] and 100% and 96% among BCC patients receiving reduced- and standard-dose bleomycin, respectively [33]. Another study treated smaller tumors with mean volumes of 3206 mm3 in BCC and 2055 mm3 in SCC, and reported OR rates of 85% and 100%, respectively [27]. These findings are consistent with previous research, which reported lower response rates in larger tumors [36,49], possibly due to reduced drug penetration and challenging electrode placement. The updated ESOPE guidelines therefore recommend the use of hexagonal electrodes for larger tumors due to the relatively larger area covered [48]. In addition, intravenous bleomycin has also shown superior outcomes compared to intratumoral administration for larger tumors [50].
Prior treatments may also influence outcomes of ECT. Higher OR rates were reported in treatment-naïve BCC and SCC patients in two studies [16,31], noting previous chemoradiotherapy affected ECT outcomes more than surgery. Another study also reported lower CR rates in BCC patients with prior irradiation [25], consistent with what have previously been reported among melanoma patients [20].
Few studies included patients who received concurrent treatment. One studied patients who underwent concurrent surgery [30], and another studied patients who received concurrent treatments including immunotherapy, photodynamic therapy, and chemotherapy [26]. However, the influence of concurrent therapies on outcomes of ECT remains unclear as subgroup analyses comparing outcomes with those receiving only ECT was not performed in those studies.
The longest follow-up duration was reported in a study among BCC patients, with a 5-year LPFS rate of 70% [41]. Better outcomes were also associated with small tumor size, early cancer stage and localized disease [41]. Likewise, a study among SCC patients reported that 1-year LPFS was significantly higher in patients with primary lesions compared to those with locally advanced disease (80% vs. 49%) [37]. A study involving patients treated with palliative intent reported lower OS rates, with a 1-year OS of 46.5% [26].
Most ECT-related side effects were pain, erythema, and hyperpigmentation but reporting was variable, complicating comparisons across studies. Notably, increased local toxicities including necrosis and ulceration were observed in studies where ECT was combined with chemotherapy or immunotherapy, or when hexagonal electrodes were used [51,52,53]. Previous research has also reported an association between concurrent radiation therapy with fibrosis and vascular damage [54]. Patients’ age may also influence the occurrence of side effects. One study compared outcomes between patients aged <90 years and ≥90 years and noted prolonged wound healing in those aged ≥90 years, suggesting that ECT might therefore benefit older patients who are more prone to side effects from traditional treatments [39].
This review has some limitations. Most studies included had a moderate to serious risk of bias, and studies were heterogenous and incomplete in their reporting of patient and treatment characteristics and outcomes. In addition, some studies reported outcomes for other skin cancer types, including non-keratinocyte carcinomas, without distinguishing results for BCC and SCC. In this regard, a previous review has outlined recommendations for improving reporting quality in ECT studies, which future studies may adopt [55]. Additionally, long-term survival data were not reported by most studies. As ECT is a relatively new treatment modality, long-term data are crucial to assess its outcomes over longer durations.
Future studies should include more homogenous patient groups to identify subgroups that benefit most from ECT. Currently, most studies included patients with various tumor histotypes. This limits the ability to perform subgroup analyses and hinders clear outcomes related to specific cancer types. More comparative studies are also required to understand how patient and treatment factors influence outcome in order to refine protocols to maximize efficacy while minimizing toxicities.

5. Conclusions

This review highlights the broad applicability, effectiveness, and tolerability of ECT in the treatment and palliation of keratinocyte carcinomas. It also underscores the need for more RCTs to compare ECT with other established treatment modalities. Future studies should focus on improving reporting quality, optimizing treatment protocols, and investigating long-term outcomes.

Author Contributions

C.C.O.: Conceptualization, data curation, study supervision. Y.T.N.T.: Conceptualization, methodology, data curation, formal analysis, writing. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data of the current original research are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Apalla, Z.; Lallas, A.; Sotiriou, E.; Lazaridou, E.; Ioannides, D. Epidemiological trends in skin cancer. Dermatol. Pract. Concept. 2017, 7, 1–6. [Google Scholar] [CrossRef]
  2. Parker, E.R. The influence of climate change on skin cancer incidence—A review of the evidence. Int. J. Women’s Dermatol. 2021, 7, 17–27. [Google Scholar] [CrossRef] [PubMed]
  3. Keohane, S.G.; Botting, J.; Budny, P.G.; Dolan, O.M.; Fife, K.; Harwood, C.A.; Mallipeddi, R.; Marsden, J.R.; Mustapa, M.F.M.; Exton, L.S.; et al. British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020. Br. J. Dermatol. 2021, 184, 401–414. [Google Scholar] [CrossRef] [PubMed]
  4. Villani, A.; Cinelli, E.; Fabbrocini, G.; Lallas, A.; Scalvenzi, M. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: Risks and benefits. Expert Opin. Drug Saf. 2020, 19, 1585–1594. [Google Scholar] [CrossRef]
  5. Kim, J.Y.S.; Kozlow, J.H.; Mittal, B.; Moyer, J.; Olenecki, T.; Rodgers, P. Guidelines of care for the management of cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol. 2018, 78, 560–578. [Google Scholar] [CrossRef] [PubMed]
  6. Collins, A.; Savas, J.; Doerfler, L. Current Basal and Squamous Cell Skin Cancer Management. Plast. Reconstr. Surg. 2018, 142, 373e–387e. [Google Scholar]
  7. Collins, A.; Savas, J.; Doerfler, L. Nonsurgical Treatments for Nonmelanoma Skin Cancer. Dermatol. Clin. 2019, 37, 435–441. [Google Scholar] [CrossRef]
  8. Doan, H.Q.; Chen, L.; Nawas, Z.; Lee, H.H.; Silapunt, S.; Migden, M. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. Oncotarget 2021, 12, 2089–2100. [Google Scholar] [CrossRef]
  9. Almeida, V.; Pires, D.; Silva, M.; Teixeira, M.; Teixeira, R.J.; Louro, A.; Teixeira, A. Dermatological Side Effects of Cancer Treatment: Psychosocial Implications—A Systematic Review of the Literature. Healthcare 2023, 11, 2621. [Google Scholar] [CrossRef]
  10. Mir, L.M.; Orlowski, S.; Belehradek, J., Jr.; Paoletti, C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur. J. Cancer Clin. Oncol. 1991, 27, 68–72. [Google Scholar] [CrossRef]
  11. Heller, R.; Jaroszeski, M.J.; Reintgen, D.S.; Puleo, C.A.; DeConti, R.C.; Gilbert, R.A.; Glass, L.F. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998, 83, 148–157. [Google Scholar] [CrossRef]
  12. Gehl, J.; Geertsen, P.F. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res. 2000, 10, 585–589. [Google Scholar] [CrossRef] [PubMed]
  13. Serša, G.; Štabuc, B.; Cemazar, M.; Miklavcic, D.; Rudolf, Z. Electrochemotherapy with cisplatin: Clinical experience in malignant melanoma patients. Clin. Cancer Res. 2000, 6, 863–867. [Google Scholar]
  14. Mir, L.M.; Belehradek, M.; Domenge, C.; Orlowski, S.; Poddevin, B.; Belehradek, J., Jr.; Paoletti, C. Electrochemotherapy, a new antitumor treatment: First clinical trial. Comptes Rendus L’academie Des Sciences. Ser. III Sci. Vie 1991, 313, 613–618. [Google Scholar]
  15. Longo, F.; Perri, F.; Pavone, E.; Aversa, C.; Maglione, M.G.; Guida, A.; Montano, M.; Villano, S.; Daponte, A.; Caponigro, F.; et al. Electrochemotherapy as palliative treatment in patients with advanced head and neck tumours: Outcome analysis in 93 patients treated in a single institution. Oral Oncol. 2019, 92, 77–84. [Google Scholar] [CrossRef]
  16. Bertino, G.; Sersa, G.; De Terlizzi, F.; Occhini, A.; Plaschke, C.C.; Groselj, A.; Benazzo, M. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. Eur. J. Cancer 2016, 63, 41–52. [Google Scholar] [CrossRef]
  17. Plaschke, C.C.; Bertino, G.; McCaul, J.A.; Grau, J.J.; de Bree, R.; Sersa, G.; Occhini, A.; Benazzo, M.; De Terlizzi, F.; Wessel, I.; et al. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers. Eur. J. Cancer 2017, 87, 172–181. [Google Scholar] [CrossRef]
  18. Mir, L.M.; Gehl, J.S.; Sersa, G.; Collins, C.G.; Garbay, J.R.; Billard, V.; Marty, M. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur. J. Cancer Suppl. 2006, 4, 14–25. [Google Scholar] [CrossRef]
  19. Petrelli, F.; Ghidini, A.; Simioni, A.; Campana, L.G. Impact of electrochemotherapy in metastatic cutaneous melanoma: A contemporary systematic review and meta-analysis. Acta Oncol. 2022, 61, 533–544. [Google Scholar] [CrossRef]
  20. Ferioli, M.; Lancellotta, V.; Perrone, A.M.; Arcelli, A.; Galuppi, A.; Strigari, L.; Tagliaferri, L.; Morganti, A.G. Electrochemotherapy of skin metastases from malignant melanoma: A PRISMA-compliant systematic review. Clin. Exp. Metastasis 2022, 39, 743–755. [Google Scholar] [CrossRef]
  21. Hendel, K.; Jemec, G.B.E.; Haedersdal, M.; Wiegell, S.R. Electrochemotherapy with bleomycin for basal cell carcinomas: A systematic review. J. Eur. Acad. Dermatol. Venereol. 2021, 35, 2208–2215. [Google Scholar] [CrossRef] [PubMed]
  22. Sterne, J.A.; Hernán, M.A.; Reeves, B.C.; Savović, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Higgins, J.P. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016, 355, i4919. [Google Scholar] [CrossRef] [PubMed]
  23. Sterne, J.A.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Higgins, J.P. RoB 2: A revised tool for assessing risk of bias in randomised trials. bmj 2019, 366, l4898. [Google Scholar] [CrossRef]
  24. Higgins, J.P. Cochrane Handbook for Systematic Reviews of Interventions; John Wiley and Sons: Hoboken, NJ, USA, 2008. [Google Scholar]
  25. Clover, A.J.P.; Salwa, S.P.; Bourke, M.G.; McKiernan, J.; Forde, P.F.; O’Sullivan, S.T.; Kelly, E.J.; Soden, D.M. Electrochemotherapy for the treatment of primary basal cell carcinoma; A randomised control trial comparing electrochemotherapy and surgery with five year follow up. Eur. J. Surg. Oncol. 2020, 46, 847–854. [Google Scholar] [CrossRef] [PubMed]
  26. Pichi, B.; Pellini, R.; Virgilio, A.D.E.; Spriano, G. Electrochemotherapy: A well-accepted palliative treatment by patients with head and neck tumours. Acta Otorhinolaryngol. Ital. 2018, 38, 181–187. [Google Scholar] [CrossRef] [PubMed]
  27. Lyons, P.; Polini, D.; Russell-Ryan, K.; Clover, A.J.P. High-Frequency Electroporation and Chemotherapy for the Treatment of Cutaneous Malignancies: Evaluation of Early Clinical Response. Cancers 2023, 15, 3212. [Google Scholar] [CrossRef]
  28. Solari, N.; Spagnolo, F.; Ponte, E.; Quaglia, A.; Lillini, R.; Battista, M.; Queirolo, P.; Cafiero, F. Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: A series of 39 patients treated with palliative intent. J. Surg. Oncol. 2014, 109, 270–274. [Google Scholar] [CrossRef]
  29. Kis, E.G.; Baltás, E.; Ócsai, H.; Vass, A.; Németh, I.B.; Varga, E.; Oláh, J.; Kemény, L.; Tóth-Molnár, E. Electrochemotherapy in the treatment of locally advanced or recurrent eyelid-periocular basal cell carcinomas. Sci. Rep. 2019, 9, 4285. [Google Scholar] [CrossRef]
  30. Campana, L.G.; Testori, A.; Curatolo, P.; Quaglino, P.; Mocellin, S.; Bonadies, A. Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. Eur. J. Surg. Oncol. 2016, 42, 1914–1923. [Google Scholar] [CrossRef]
  31. Bertino, G.; Muir, T.; Odili, J.; Groselj, A.; Marconato, R.; Curatolo, P.; Kis, E.; Group, T.I.B.W. Treatment of Basal Cell Carcinoma with Electrochemotherapy: Insights from the InspECT Registry (2008–2019). Curr. Oncol. 2022, 29, 5324–5337. [Google Scholar] [CrossRef]
  32. Jamsek, C.; Sersa, G.; Bosnjak, M.; Groselj, A. Long Term Response of Electrochemotherapy with Reduced Dose of Bleomycin in Elderly Patients with Head and Neck Non-melanoma Skin Cancer. Radiol. Oncol. 2020, 54, 79–85. [Google Scholar] [CrossRef] [PubMed]
  33. Groselj, A.; Bosnjak, M.; Strojan, P.; Krzan, M.; Cemazar, M.; Sersa, G. Efficiency of electrochemotherapy with reduced bleomycin dose in the treatment of nonmelanoma head and neck skin cancer: Preliminary results. Head Neck 2018, 40, 120–125. [Google Scholar] [CrossRef]
  34. Tomassini, G.M.; Covarelli, P.; Tomassini, M.A.; Corsi, A.; Bianchi, L.; Hansel, K.; Stingeni, L. Electrochemotherapy with intravenous bleomycin for advanced non-melanoma skin cancers and for cutaneous and subcutaneous metastases from melanoma. G. Ital. Dermatol. Venereol. 2016, 151, 499–506. [Google Scholar]
  35. Claussen, C.S.; Moir, G.; Bechara, F.G.; Orlando, A.; Matteucci, P.; Mowatt, D.; Kunte, C. Prospective cohort study by InspECT on safety and efficacy of electrochemotherapy for cutaneous tumors and metastases depending on ulceration. J. Ger. Soc. Dermatol. 2022, 20, 470–481. [Google Scholar] [CrossRef] [PubMed]
  36. Clover, A.J.P.; de Terlizzi, F.; Bertino, G.; Curatolo, P.; Odili, J.; Campana, L.G.; Kunte, C.; Gehl, J. Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019). Eur. J. Cancer 2020, 138, 30–40. [Google Scholar]
  37. Bertino, G.; Groselj, A.; Campana, L.G.; Kunte, C.; Schepler, H.; Gehl, J.; Sersa, G. Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma: The INSPECT experience (2008–2020). Front. Oncol. 2022, 12, 951662. [Google Scholar] [CrossRef]
  38. Riva, G.; Salonia, L.; Fassone, E.; Sapino, S.; Piano, F.; Pecorari, G. Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors. J. Clin. Med. 2021, 10, 4366. [Google Scholar] [CrossRef]
  39. Sersa, G.; Mascherini, M.; Di Prata, C.; Odili, J.; de Terlizzi, F.; McKenzie, G.A.G.; Clover, A.J.P.; Bertino, G.; Campana, L.G. Outcomes of older adults aged 90 and over with cutaneous malignancies after electrochemotherapy with bleomycin: A matched cohort analysis from the InspECT registry. Eur. J. Surg. Oncol. 2021, 47, 902–912. [Google Scholar] [CrossRef] [PubMed]
  40. Bonadies, A.; Bertozzi, E.; Cristiani, R.; Govoni, F.A.; Migliano, E. Electrochemotherapy in Skin Malignancies of Head and Neck Cancer Patients: Clinical Efficacy and Aesthetic Benefits. Acta Derm.-Venereol. 2019, 99, 1246–1252. [Google Scholar] [CrossRef]
  41. Campana, L.G.; Marconato, R.; Valpione, S.; Galuppo, S.; Alaibac, M.; Rossi, C.R.; Mocellin, S. Basal cell carcinoma: 10-year experience with electrochemotherapy. J. Transl. Med. 2017, 15, 122. [Google Scholar] [CrossRef]
  42. Rotunno, R.; Campana, L.G.; Quaglino, P.; de Terlizzi, F.; Kunte, C.; Odili, J.; Gehl, J.; Ribero, S.; Liew, S.H.; Curatolo, P. Electrochemotherapy of unresectable cutaneous tumours with reduced dosages of intravenous bleomycin: Analysis of 57 patients from the International Network for Sharing Practices of Electrochemotherapy registry. J. Eur. Acad. Dermatol. Venereol. 2018, 32, 1147–1154. [Google Scholar] [CrossRef]
  43. Kreuter, A.; van Eijk, T.; Lehmann, P.; Fischer, M.; Horn, T.; Assaf, C.; Schley, G.; Lommel, K. Electrochemotherapy in advanced skin tumors and cutaneous metastases—A retrospective multicenter analysis. J. Ger. Soc. Dermatol. 2015, 13, 308–315. [Google Scholar] [CrossRef] [PubMed]
  44. Monta, D.; Caracò, C.; Simeone, E.; Grimaldi, A.M.; Marone, U.; Di Marzo, M.; Vanella, V.; Festino, L.; Ascierto, P.A. Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: A 22-cases retrospective analysis. J. Transl. Med. 2017, 15, 82. [Google Scholar] [CrossRef] [PubMed]
  45. Derebaşınlıoğlu, H. Distribution of skin cancers of the head and neck according to anatomical subunit. Eur. Arch. Oto-Rhino-Laryngol. 2021, 279, 1461–1466. [Google Scholar] [CrossRef]
  46. Bleomycin for Injection USP (Bleomycin Sulphate): Pfizer Canada. Homepage. Available online: https://www.pfizer.ca/en/our-products/bleomycin-injection-usp-bleomycin-sulphate (accessed on 21 May 2025).
  47. Groselj, A.; Krzan, M.; Kosjek, T.; Bosnjak, M.; Sersa, G.; Cemazar, M.; Groselj, A.; Krzan, M.; Kosjek, T.; Bosnjak, M.; et al. Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy. Cancer Chemother. Pharmacol. 2016, 77, 939–947. [Google Scholar] [CrossRef]
  48. Gehl, J.; Sersa, G.; Matthiessen, L.W.; Muir, T.; Soden, D.; Dahlstrom, K.; Benazzo, M.; Mir, L.M. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol. 2018, 57, 874–882. [Google Scholar] [CrossRef]
  49. Morley, J.; Grocott, P.; Purssell, E.; Murrells, T. Electrochemotherapy for the palliative management of cutaneous metastases: A systematic review and meta-analysis. Eur. J. Surg. Oncol. 2019, 45, 2257–2267. [Google Scholar] [CrossRef]
  50. Ariffin, A.B.; Forde, P.F.; Jahangeer, S.; Soden, D.M.; Hinchion, J. Releasing pressure in tumors: What do we know so far and where do we go from here? A review. Cancer Res. 2014, 74, 2655–2662. [Google Scholar] [CrossRef] [PubMed]
  51. Gaudy, C.; Richard, M.A.; Folchetti, G.; Bonerandi, J.J.; Grob, J.J. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J. Cutan. Med. Surg. 2006, 10, 115–121. [Google Scholar] [CrossRef]
  52. Heppt, M.V.; Eigentler, T.K.; Kähler, K.C.; Herbst, R.A.; Göppner, D.; Matheis, F.; Tietze, J.K.; Berking, C. Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: A retrospective multicenter analysis. Cancer Immunol. Immunother. CII 2016, 65, 951–959. [Google Scholar] [CrossRef]
  53. Mir-Bonafé, J.M.; Vilalta, A.; Alarcón, I.; Carrera, C.; Puig, S.; Malvehy, J.; Rull, R.; Bennàssar, A. Electrochemotherapy in the treatment of melanoma skin metastases: A report on 31 cases. Actas Dermo-Sifiliogr. 2015, 106, 285–291. [Google Scholar] [CrossRef] [PubMed]
  54. Yu, Z.; Xu, C.; Song, B.; Zhang, S.; Chen, C.; Li, C.; Zhang, S. Tissue fibrosis induced by radiotherapy: Current understanding of the molecular mechanisms, diagnosis and therapeutic advances. J. Transl. Med. 2023, 21, 708. [Google Scholar] [CrossRef] [PubMed]
  55. Campana, L.G.; Clover, A.J.P.; Valpione, S.; Quaglino, P.; Gehl, J.; Kunte, C.; Sersa, G. Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. Radiol. Oncol. 2016, 50, 1–13. [Google Scholar] [CrossRef] [PubMed]
Figure 1. PRISMA flow chart diagram of the search strategy.
Figure 1. PRISMA flow chart diagram of the search strategy.
Cancers 17 01766 g001
Table 1. Patient and tumor characteristics for basal cell carcinoma (BCC).
Table 1. Patient and tumor characteristics for basal cell carcinoma (BCC).
StudyDesignDisease StageTreatment IntentNumber of Participants Treated Age, Median (Range), YearsNumber of Tumors Treated Tumors per Patient, Median (Range), NumberSite of TumorsDimension of Tumors, Median (Range)
Kis et al. 2019 [29]ProspectiveNRCurative12 61.6 a (11–86)151 (1–2) H-N, trunk, extremities12 mm (2–43)
Clover et al. 2020 [25]Randomized controlled trialNRCurativeECT: 50
Surgery: 42
ECT: 66.8 (24–92) a, b
Surgery: 63.8 (37–91) a, b
ECT: 69
Surgery: 48
1 (81.5%), 2 (14.1%), 3 (3.3%), 7 (1.1%)NRECT: 17 mm2 (2.4–105)
Surgery: 14 mm2 (2.5–5)
Campana et al., 2016 [30]ProspectiveIV (38.3%) cCurative24 71 (24–100) c1304 c3 (1–5) cH-N, trunk, extremities10 mm (6–20) c
Bertino et al. 2022 [31]ProspectiveNRCurative330 72 (23–98)6231 (1–7)H-N, trunk, extremities13 mm (5–350)
Riva et al. 2021 [38]RetrospectiveNRPalliative478 cNRNR H-N<30 mm: 27%
>30 mm: 63%
Sersa et al. 2021 [39]RetrospectiveNRCurative≥90 years: 11
<90 years: 22
≥90 years: 92 (90–104) c
<90 years: 77 (23–89) c
NR1 (1–7) cH-N, trunk, extremities≥90 years: 15 mm (5–450) c
<90 years: 15 mm (5–500) c
Jamsek et al. 2020 [32]Prospective NRCurativeReduced dose: 10
Standard dose: 14
Reduced dose: 81.5 (67–92)
Standard dose: 79.5 (65–89)
Reduced dose: 17
Standard dose: 25
Reduced dose: 1.5 (1–4)
Standard dose: 1 (1–5)
H-NReduced dose: 15 mm (7–80)
Standard dose: 11 mm (4–50)
Bonadies et al. 2019 [40]RetrospectiveNSCurative3 80 (30–102) cNR1 (37%), ≥2 (63%) cH-N, trunk, extremities NR
Groselj et al. 2018 [33]ProspectiveNRCurative Reduced dose: 10
Standard dose: 13
Reduced dose: 81.5 (67–92)
Standard dose: 79.5 (65–89)
Reduced dose: 16
Standard dose: 25
Reduced dose: 1.5 (1–4)
Standard dose: 1 (1–5)
H-NReduced dose: 15 mm (7–80)
Standard dose: 11 mm (4–50)
Bertino et al., 2016 [16]ProspectiveI–II (83.8%), III–IV (16.2%) cCurative34 77 (39–96) c341 (1) H-N≤30 mm: 91.2%
>30 mm: 8.8%
Tomassini et al., 2016 [34]ProspectiveNRCurative485 (40–95) 19 cNRH-N110 mm (30–180) d
Claussen et al. 2022 [35]ProspectiveNRCurative19372 a, c1784 cNRH-N, trunk, extremitiesNon-ulcerated lesions: 15 mm (5–450) a
Ulcerated lesions: 30 mm (5–500) a
Lyons et al. 2023 [27]Single-arm trial NRCurative25 c73.6 a, c30NRNR3206 mm3 a
Clover et al. 2020 [36]ProspectiveNRCurative 29875 (20–104) c567NRH-N, trunk, extremities23 mm (5–500) c
Campana et al. 2017 [41]Retrospective I–III (96%), IV (4%) Palliative 8469 (24–89) 185 2 (1–3) H-N, trunk, extremities20 mm (5–267)
Rotunno et al. 2018 [42]RetrospectiveNR Curative 1078 (43–97) c147 c2 (1–7) cH-N, trunk, extremities10 mm (5–190) c
Solari et al. 2014 [28]Single-arm trial NRPalliative272 (47–91) cNR 20 (1–60) c, eH-N, trunk, extremities< 20 mm: 43.6% c
≥ 20 mm: 56.4% c
ECT: electrochemotherapy; H-N: head-and-neck; NR: not reported. a Data presented as mean; b Only data on enrolled patients available (ECT = 52; Surgery = 48). c The data specific to BCC are not available and encompasses a broader category of skin cancers as reported in the individual studies. d The sum of the longest diameters. e A total of 25 (64.1%) patients had more than 10 tumors and 14 (35.9%) patients had 10 or less tumors.
Table 2. Patient and tumor characteristics for squamous cell carcinoma (SCC).
Table 2. Patient and tumor characteristics for squamous cell carcinoma (SCC).
StudyDesignDisease StageMucosal/CutaneousTreatment
Intent
Number of Participants Treated Age, Median (Range), YearsNumber of Tumors TreatedTumors per Patient, Median (Range), NumberSite of TumorsDimension of Tumors, Median (Range)
Campana et al., 2016 [30]ProspectiveIV (38.3%) aCutaneousCurative4171 (24–100) a1304 a3 (1–5) aH-N, trunk, extremities10 mm (6–20) a
Bertino et al. 2022 [37]ProspectiveNSCutaneousCurative162 80 (41–104) 342 1 (1–7) H-N, trunk, extremities21 mm (5–250)
Riva et al. 2021 [38]RetrospectiveNRCutaneous and mucosalPalliative18 78 aNRNR H-N<30 mm: 27%
>30 mm: 63%
Sersa et al. 2021 [39]RetrospectiveNRCutaneousCurative≥90 years: 16
<90 years: 32
≥90 years: 92 (90–104) a
<90 years: 77 (23–89) a
NR1 (1–7) aH-N, trunk, extremities≥90 years: 15 mm (5–450) a
<90 years: 15 mm (5–500) a
Jamsek et al. 2020 [32]Prospective NRCutaneousCurativeReduced dose: 3
Standard dose: 3
Reduced dose: 82 (76–83)
Standard dose: 85 (67–89)
Reduced dose: 7
Standard dose: 3
Reduced dose: 3 (1–3)
Standard dose: 1 (1–2)
H-NReduced dose: 10 mm (6–35)
Standard dose: 25 mm (22–45)
Bonadies et al. 2019 [40] RetrospectiveNSCutaneousCurative12 80 (30–102) aNR1 (37%), ≥2 (63%) aH-N, trunk, extremitiesNR
Pichi et al. 2018 [26]Single-arm trial IV (16.7%)Cutaneous and mucosal Palliative2072.5 (52–92) NRNRH-N NR
Groselj et al. 2018 [33]ProspectiveNRNS CurativeReduced dose: 3
Standard dose: 3
Reduced dose: 82 (76–83)
Standard dose: 85 (67–89)
Reduced dose: 8
Standard dose: 3
Reduced dose: 3 (2–3)
Standard dose: 1 (1–2)
H-N Reduced dose: 20 mm (6–35)
Standard dose: 25 mm (22–45)
Bertino et al., 2016 [16]ProspectiveI–II (83.8%), III–IV (16.2%) aNSCurative50 77 (39–96) a501 (1) H-N ≤30 mm: 52%
>30 mm: 48%
Tomassini et al., 2016 [34]ProspectiveNRCutaneousCurative278.5 (75–82) 19 aNRH-N110 mm (30–180) b
Kreuter et al. 2015 [43]RetrospectiveIII–IV (100%) CutaneousCurative573.1 aNRNRH-N, trunk, extremities NR
Claussen et al. 2022 [35]ProspectiveNRCutaneousCurative12972 a, c 1784 aNRH-N, trunk, extremitiesNon-ulcerated lesions: 15 mm (5–450) a
Ulcerated lesions: 30 mm (5–500) a
Lyons et al. 2023 [27]Single-arm trial NRNRCurative25 a73.6 a, c 2NRNR2055 mm3 c
Clover et al. 2020 [36]ProspectiveNRNRCurative15675 (20–104) a284NRH-N, trunk, extremities23 mm (5–500) a
Rotunno et al. 2018 [42] RetrospectiveNRNRCurative1378 (43–97) a147 a2 (1–7) aH-N, trunk, extremities10 mm (5–190) a
Di Monta et al. 2017 [44]Retrospective III (100%)CutaneousCurative 2272 (51–88) 22 1 (1)H-N, trunk, extremitiesNR
Solari et al. 2014 [28]Single-arm trial NRNRPalliative572 (47–91) aNR20 (1–60) a, dH-N, trunk, extremities <20 mm: 43.6% a
≥20 mm: 56.4% a
H-N: head-and-neck; NR: not reported. a The data specific to SCC are not available and encompasses a broader category of skin cancers as reported in the individual studies. b The sum of the longest diameters. c The data are presented as mean. d A total of 25 (64.1%) patients had more than 10 tumors and 14 (35.9%) patients had 10 or less tumors.
Table 3. Treatment characteristics for basal cell carcinoma (BCC).
Table 3. Treatment characteristics for basal cell carcinoma (BCC).
Study Drug RouteDose (Range)ElectrodeAnesthesia Number of CyclesPrevious TherapiesConcurrent Therapies
Kis et al. 2019 [29]BLMIV (75%), IT (25%)NRNeedle (hexagonal), row GA 1–5 Surgery, IMT (75%)None
Clover et al. 2020 [25]BLMIT 1653 IU (500–5000) Needle (hexagonal), parallel LA, GA1–2 NRNone
Campana et al., 2016 [30] aBLM, CDDPIV BLM (93.4%), IT BLM (6.1%), IV CDDP (0.5%)NRNeedle (hexagonal, linear), plate, multipleLA, GA1 (76.3%), 2 (19.1%), 3 (3.5%), 3 (0.8%), 6 (0.3%)Surgery, CHT, RT, IMT (81.4%)Surgery (6.1%)
Bertino et al. 2022 [31]BLMIV (56%), IT (44%) IV: 15,000–30,000 IU/m2
IT: 1000 IU
Needle (hexagonal), row, plate LA, GA1 (84%), 2 (16%) Surgery, RT, CYT, PDT, ECT, TT (39%) None
Riva et al., 2021 [38] aBLMIV15,000 IU/m2Needle (linear), finger NRNRRT (44.4%) None
Sersa et al. 2021 [39] aBLM≥90 years: IV (66%), IT (34%)
<90 years: IV (73%), IT (27%)
NRNeedle (hexagonal, linear), plate, multipleLA, GA≥90 years: 1 (90%), 2 (10%)
<90 years: 1 (89%), 2 (11%)
≥90 years: Surgery, RT, CYT, PDT (51%)
<90 years: Surgery, RT, CYT, PDT (56%)
None
Jamsek et al. 2020 [32] aBLMIV Reduced dose: 10,000 IU/m2
Standard dose: 15,000 IU/m2
Plate, needle (linear, hexagonal)LA, GA NR NRNR
Bonadies et al. 2019 [40] aBLMIV 15,000 IU/m2Plate, finger, needle (linear, hexagonal) NR1 (48%), 2 (37%), 3 (12%), 6 (3%) Surgery, CHT, PDT (67%)
None (33%)
None
Groselj et al. 2018 [33] aBLMIV Reduced dose: 10,000 IU/m2
Standard dose: 15,000 IU/m2
Plate, needle (linear, hexagonal)LA, GA NRSurgery, RT (25%)None
Bertino et al., 2016 [16] aBLMIV (92%), IT (8%) NRPlate, needle (hexagonal), row, combination LA, GA 1 (82%), 2 (18%) Surgery (31%), CHT/RT (9%), surgery with CHT/RT (31%), unknown (2%) None
Tomassini et al., 2016 [34] aBLMIV 15,000 IU/m2Finger LA1 (53.8%), 2 (46.2%)NRNone
Claussen et al. 2022 [35] aBLMIV, IT IV: 15,000 IU/m2
IT: 1000 IU
Needle (linear, hexagonal), plate NR NRNRNone
Lyons et al. 2023 [27] aBLMIV, IT IV: 15,000 IU/m2
IT: 1000 IU
NRLA, GA, spinal anesthesia NRNRNone
Clover et al. 2020 [36] aBLMIV (75%), IT (25%) IV: 15,000 IU/m2
IT: 1000 IU
Plate, needle (hexagonal), row, combinationLA, GA, regional anesthesiaNRNRNone
Campana et al. 2017 [41]BLMIV, IT IV: 15,000 IU/m2
IT: 250–1000 IU
Needle (linear, hexagonal), finger LA, GA, sedation, general 1 (71.4%), 2 (27.4%), 4 (1.2%)Surgery (46%), RT (24%), IMT (7%), PDT (2.4%), CYT (6.0%), TT (1.2%)None
Rotunno et al. 2018 [42] aBLMIVIV: 7500, 10,000, 13,500 IU/m2Needle (linear, hexagonal), plate, multiple LA, GA, regional 1 (74%), 2 (19%), 3 (7%) RT (6.8%) None
Solari et al. 2014 [28] aBLMIV15,000 IU/m2Needle (hexagonal) GA 1 (56.4%), 2 (30.8%), 3 (10.3%), 4 (4.5%) NRNone
BLM: bleomycin; CDDP: cisplatin; CHT: chemotherapy; CYT: cryotherapy; GA: general anesthesia; IV: intravenous; IT: intratumoral; IMT: immunotherapy; LA: local anesthesia; NR: not reported; PDT: photodynamic therapy; RT: radiotherapy; TT: topical therapies. a The data specific to BCC are not available and encompasses a broader category of skin cancers as reported in the individual studies.
Table 4. Treatment characteristics for squamous cell carcinoma (SCC).
Table 4. Treatment characteristics for squamous cell carcinoma (SCC).
Study Drug RouteDose (Range)ElectrodeAnesthesia Number of CyclesPrevious TherapiesConcurrent Therapies
Campana et al., 2016 [30] aBLM, CDDPIV BLM (93.4%), IT BLM (6.1%), IV CDDP (0.5%)NRNeedle (hexagonal, linear), plate, multipleLA, GA1 (76.3%), 2 (19.1%), 3 (3.5%), 3 (0.8%), 6 (0.3%)Surgery, CHT, RT, IMT (81.4%)Surgery (6.1%)
Bertino et al. 2022 [37]BLMIV (83%), IT (17) IV: 15,000 IU/m2
IT: 1000 IU
Needle (hexagonal, linear), plate, multipleLA, GA1 (90.1%), 2 (9.3%), 3 (0.6%) Surgery, RT, CHT, CYT, PDT, IMT, ECT (70%)None
Riva et al., 2021 [38] aBLMIV15,000 IU/m2Needle (linear), finger NRNRRT (44.4%)None
Sersa et al. 2021 [39] aBLM≥90 years: IV (66%), IT (34%)
<90 years: IV (73%), IT (27%)
NRNeedle (hexagonal, linear), plate, multipleLA, GA≥90 years: 1 (90%), 2 (10%)
<90 years: 1 (89%), 2 (11%)
≥90 years: Surgery, RT, CYT, PDT (51%)
<90 years: Surgery, RT, CYT, PDT (56%)
None
Jamsek et al. 2020 [32] aBLMIV Reduced dose: 10,000 IU/m2
Standard dose: 15,000 IU/m2
Plate, needle (linear, hexagonal)LA, GA NR NRNR
Bonadies et al. 2019 [40] aBLMIV 15,000 IU/m2Plate, finger, needle (linear, hexagonal) NR1 (48%), 2 (37%), 3 (12%), 6 (3%) Surgery, CHT, PDT (67%)None
Pichi et al. 2018 [26]BLMIV 15,000 IU/m2Finger, needle (hexagonal) LA1 (60%), 2 (25%), 3 (10%), 4 (5%) NRIMT with cetuximab, PDT, CHT with MTX (20%)
Groselj et al. 2018 [33] aBLMIV Reduced dose: 10,000 IU/m2
Standard dose: 15,000 IU/m2
Plate, needle (linear, hexagonal)LA, GA NRSurgery, RT (25%)None
Bertino et al., 2016 [16] aBLMIV (92%), IT (8%) NRPlate, needle (hexagonal), row, combination LA, GA 1 (82%), 2 (18%) Surgery (31%), CHT/RT (9%), surgery with CHT/RT (31%), unknown (2%) None
Tomassini et al., 2016 [34] aBLMIV 15,000 IU/m2Finger LA1 (53.8%), 2 (46.2%)NRNone
Kreuter et al. 2015 [43] aBLMIV NR Needle (linear, hexagonal), plate NR 2.1 bSurgery, RT, CHT c None
Claussen et al. 2022 [35] aBLMIV, IT IV: 15,000 IU/m2
IT: 1000 IU
Needle (linear, hexagonal), plate NR NRNRNone
Lyons et al. 2023 [27] aBLMIV, IT IV: 15,000 IU/m2
IT: 1000 IU
NRLA, GA, spinal anesthesia NRNRNone
Clover et al. 2020 [36] aBLMIV (75%), IT (25%) IV: 15,000 IU/m2
IT: 1000 IU
Plate, needle (hexagonal), row, combinationLA, GA, regional anesthesiaNRNRNone
Rotunno et al. 2018 [42] aBLMIVIV: 7500, 10,000, 13,500 IU/m2Needle (linear, hexagonal), plate, multiple LA, GA, regional 1 (74%), 2 (19%), 3 (7%) RT (6.8%) None
Di Monta et al. 2017 [44]BLMIV15,000 IU/m2Needle (linear) GA 1 (68.2%), 2 (27.3%), 3 (4.5%) NRNone
Solari et al. 2014 [28] aBLMIV15,000 IU/m2Needle (hexagonal) GA 1 (56.4%), 2 (30.8%), 3 (10.3%), 4 (4.5%) NRNone
BLM: bleomycin; CDDP: cisplatin; CHT: chemotherapy; CYT: cryotherapy; GA: general anesthesia; IV: intravenous; IT: intratumoral; IMT: immunotherapy; LA: local anesthesia; NR: not reported; PDT: photodynamic therapy; RT: radiotherapy; TT: topical therapies. a The data specific to SCC are not available and encompasses a broader category of skin cancers as reported in the individual studies. b The data are presented as mean. c The proportion of patients is not reported.
Table 5. Tumor response and toxicity for basal cell carcinoma (BCC).
Table 5. Tumor response and toxicity for basal cell carcinoma (BCC).
Study Response Scale Response Evaluation Time of Response EvaluationFollow-Up Duration, Median (Range)CR (%) PR (%)SD (%)PD (%)Toxicity Scale Toxicity OSLocal Tumour Control
Kis et al. 2019 [29]RECISTPatient NR19 months (15–56) 58.3% aNRNRNRNRHyperemia and edema (80%), pain (50%)NRNR
Clover et al. 2020 [25]RECISTPatient/Lesion60 days Up till 5 years ECT: 88.9%/88.4% b
Surgery: 95.1%/95.8% c
NRNRNRCTCAEECT: Infection, ulceration, erythema, pain
Surgery: Infection, erythema, swelling
NRNR
Campana et al. 2016 [30]RECISTPatient 60 days13.9 months (0.4–63.2)66.7%NRNRNRCTCAEGrade 0–1 (100%), 2–4 (0%)NSNS
Bertino et al. 2022 [31]RECISTPatient/Lesion60 days 17 months (2–103) 81.5% e/84.3% f15.5% e/13.1% f 3.0% e/2.6% f0% e/0% fCTCAEHyperpigmentation, ulceration 14-month: 95% g 1-year LPFS: 96%
2-year LPFS: 90%
Riva et al., 2021 [38] dRECISTPatient 1 month Up till 6 months NS NSNSNSNREdemaNRNR
Sersa et al. 2021 [39] dRECISTPatient 38 and 80 days≥90 years: 8 months (2–37)
<90 years: 9 months (2–46)
NSNSNSNSCTCAEUlceration, odor, infection, hyperpigmentationNSNS
Jamsek et al. 2020 [32] dRECIST Patient2 months Reduced dose: 28 months
Standard dose: 40 months
Reduced dose: 100%
Standard dose: 96%
NRNRNRNRNR NR NR
Bonadies et al. 2019 [40]RECISTPatient2 months NR 100%0%NRNRCTCAENecrosis, edema dNRNS
Groselj et al. 2018 [33]RECISTLesion2 months NRReduced dose: 100%
Standard dose: 96%
Reduced dose: 0%
Standard dose: 0%
Reduced dose: 0%
Standard dose: 4%
Reduced dose: 0%
Standard dose: 0%
CTCAEUlceration, infection, odor dNRNR
Bertino et al., 2016 [16]RECISTLesion 2 months 6 months (15 days–12 months)≤3 cm: 93.5%
>3 cm: 66.7%
≤3 cm: 6.5%
>3 cm: 0%
≤3 cm: 0%
>3 cm: 33.3%
≤3 cm: 0%
>3 cm: 0%
CTCAEUlceration, hyperpigmentation, suppuration, headache, odor, dysphagia, rash d1 year: 100% 1-year LDFS: 89%
Tomassini et al., 2016 [34] dRECISTLesion 2 months NRNS NS NS NS NRNR NRNR
Claussen et al. 2022 [35] dRECISTLesion1–2 months Minimum of 180 daysNSNSNSNSCTCAE Pain, hyperpigmentation NRNR
Lyons et al. 2023 [27]RECISTLesion12 weeks 18 months 85% h 15% hNR0% hNRNRNRNR
Clover et al. 2020 [36]RECISTLesionAt least 45 days NR 85%11%NRNRNRNRNRNR
Campana et al. 2017 [41]RECISTPatient 1 month 49.2 months (3.6–121.1) 50.0% i35.7% i14.3% i0% iCTCAEErythema, edema, pain, ulceration, infection NR 5-year LPFS: 70%
Rotunno et al. 2018 [42]RECISTLesion60 days 165 days (60–1061) 83%17%0%0%NRPain, hyperpigmentation, ulceration, erythema, nausea, flu-like symptoms dNR NS
Solari et al. 2014 [28] dRECISTPatient NRNR NS NSNSNSNRNRNRNR
CR: complete response; CTCAE: Common Terminology Criteria for Adverse Events; ECT: electrochemotherapy; LDFS: local disease-free survival; LPFS: local progression-free survival; NR: not reported; NS: not specified; OS: overall survival; PD: progressive disease; PR: partial response; RECIST: Response Evaluation Criteria in Solid Tumors; SD: stable disease; a Response after one ECT session, CR was 83.3% after two sessions, 91.6% after four sessions, and 100% after five sessions; b Response after one ECT session, CR was 100% after two sessions; c Response after primary excision, CR was 100% after the 2nd further wider excision; d The data specific to BCC are not available and encompasses a broader category of skin cancers as reported in the individual studies; e Out of all evaluable lesions, three (1%) patients were unable to be evaluated due to the presence of inflammation or ulceration; f Out of all evaluable lesions, eight (1.4%) lesions were unable to be evaluated due to the presence of inflammation or ulceration; g Deaths were not related to disease; h Assessed 18 months after ECT; i Response after one ECT session, CR was 63% after two sessions.
Table 6. Tumor response and toxicity for squamous cell carcinoma (SCC).
Table 6. Tumor response and toxicity for squamous cell carcinoma (SCC).
Study Response Scale Response Evaluation Time of Response EvaluationFollow-Up Duration, Median (Range)CR (%) PR (%)SD (%)PD (%)Toxicity Scale Toxicity OSLocal Tumor Control
Campana et al. 2016 [30]RECISTPatient 60 days13.9 months (0.4–63.2) 40.7%NRNRNRCTCAEGrade 0–1 (60%), 2–4 (40%)NSNS
Bertino et al. 2022 [37]RECISTPatient/Lesion45–90 days 5.6 months (1.6–47.6) 62%/61% 21%/18% 11%/13% 5%/7% CTCAEGrade 1–2 (11%) 8.6 months:
85.1% b
1-year LPFS: 80%/49% c
Riva et al. 2021 [38] aRECISTPatient 1 month Up till 6 months NSNSNSNSNREdema NR NR
Sersa et al. 2021 [39] aRECISTPatient 38 and 80 days≥90 years: 8 months (2–37)
<90 years: 9 months (2–46)
NSNSNSNSCTCAEUlceration, odor, infection, hyperpigmentation NSNS
Jamsek et al. 2020 [32] aRECIST Patient2 months Reduced dose: 28 months
Standard dose: 40 months
Reduced dose: 100%
Standard dose: 96%
NRNRNRNRNR NR NR
Bonadies et al. 2019 [40]RECISTPatient2 months NR 92%8%NRNRCTCAENecrosis, edema a NRNS
Pichi et al. 2018 [26]RECISTPatient1 month 7.6 months (2–18) 10% 90% NRNR NRFever, pain aNSNR
Groselj et al. 2018 [33]RECISTLesion2 months NRReduced dose: 100%
Standard dose: 100%
Reduced dose: 0%
Standard dose: 0%
Reduced dose: 0%
Standard dose: 0%
Reduced dose: 0%
Standard dose: 0%
CTCAE
Ulceration, infection, odor aNRNR
Bertino et al., 2016 [16]RECISTLesion 2 months 6 months (15 days–12 months)≤3 cm: 76.9%
>3 cm: 28.6% d
≤3 cm: 7.7%
>3 cm: 42.9% d
≤3 cm: 15.4%
>3 cm: 14.3% d
≤3 cm: 0%
>3 cm: 9.5% d
CTCAEUlceration, hyperpigmentation, suppuration, headache, odor, dysphagia, rash a1 year: 64% 1-year LDFS: 87%
Tomassini et al., 2016 [34] aRECISTLesion 2 months NRNSNSNSNSNRNR NRNR
Kreuter et al. 2015 [43] aRECISTPatient NRNR NSNSNSNSNR Pain, muscle ache, necrosis, hyperpigmentation, bleeding, infectionNRNR
Claussen et al. 2022 [35]RECISTLesion1–2 months Minimum of 180 days<3 cm: 71% e
>3 cm: 41.5% f
<3 cm: 20.5% e
>3 cm: 29.5% f
<3 cm: 7.5% e
>3 cm: 21.5% f
<3 cm: 0.5% e
>3 cm: 6.0% f
CTCAE Pain, hyperpigmentation aNRNR
Lyons et al. 2023 [27]RECISTLesion12 weeks 18 months 100% g0% gNR0% g NRNRNRNR
Clover et al. 2020 [36]RECISTLesionAt least 45 days NR 63%17%NRNRNRNRNRNR
Rotunno et al. 2018 [42]RECISTLesion60 days 165 days (60–1061) 86%0%14%0%NRPain, hyperpigmentation, ulceration, erythema, nausea, flu-like symptoms aNR NS
Di Monta et al. 2017 [44]RECISTPatient 4 weeks 34 months (5–48) 22.7% 59.1% 13.6% 4.5% CTCAE Pain, erythema NRNR
Solari et al. 2014 [28] aRECISTPatient NRNR NSNSNSNSNRNRNRNR
CR: complete response; CTCAE: Common Terminology Criteria for Adverse Events; ECT: electrochemotherapy; LDFS: local disease-free survival; LPFS: local progression-free survival; NR: not reported; NS: not specified; OS: overall survival; PD: progressive disease; PR: partial response; RECIST: Response Evaluation Criteria in Solid Tumors; SD: stable disease. a The data specific to SCC are not available and encompasses a broader category of skin cancers as reported in the individual studies. b In total, 16 (66.7%) deaths were not related to disease, 8 (33.3%) deaths were related to disease. c Patients with primary tumors and locally advanced disease. d One (4.7%) lesion was unable to be evaluated due to the presence of crust formation and ulceration. e 0.5% of lesions were not evaluated. f In total, 2% of lesions were not evaluated. g Assessed 18 months after ECT3.5.2. Overall Survival and Long-Term Local Tumor Control.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Tan, Y.T.N.; Oh, C.C. Electrochemotherapy in the Management of Keratinocyte Carcinomas: A Systematic Review. Cancers 2025, 17, 1766. https://doi.org/10.3390/cancers17111766

AMA Style

Tan YTN, Oh CC. Electrochemotherapy in the Management of Keratinocyte Carcinomas: A Systematic Review. Cancers. 2025; 17(11):1766. https://doi.org/10.3390/cancers17111766

Chicago/Turabian Style

Tan, Yue Ting Nichole, and Choon Chiat Oh. 2025. "Electrochemotherapy in the Management of Keratinocyte Carcinomas: A Systematic Review" Cancers 17, no. 11: 1766. https://doi.org/10.3390/cancers17111766

APA Style

Tan, Y. T. N., & Oh, C. C. (2025). Electrochemotherapy in the Management of Keratinocyte Carcinomas: A Systematic Review. Cancers, 17(11), 1766. https://doi.org/10.3390/cancers17111766

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop